AbCellera Biologics (ABCL) Accumulated Expenses (2022 - 2026)

AbCellera Biologics' Accumulated Expenses history runs 5 years deep, the most recent figure standing at $39.6 million for Q1 2026.

• Quarterly Accumulated Expenses fell 17.33% year-over-year to $39.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $39.6 million (down 17.33% YoY) and the FY2025 annual result came in at $50.8 million, down 7.68% from the prior year.
• Accumulated Expenses was $39.6 million for Q1 2026 at AbCellera Biologics, down from $50.8 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $55.0 million in Q4 2024 and bottomed at $39.6 million in Q1 2026.
• A 5-year average of $49.0 million and a median of $50.1 million in 2025 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2025 — Accumulated Expenses climbed 13.93% — and 2026, when it fell 17.33%.
• AbCellera Biologics' Accumulated Expenses stood at $52.5 million in 2022, then declined by 5.56% to $49.6 million in 2023, then gained by 10.94% to $55.0 million in 2024, then decreased by 7.68% to $50.8 million in 2025, then dropped by 22.11% to $39.6 million in 2026.
• Business Quant data shows ABCL's Accumulated Expenses at $39.6 million in Q1 2026, $50.8 million in Q4 2025, and $53.1 million in Q3 2025.